Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19
- PMID: 34591799
- PMCID: PMC8575099
- DOI: 10.1097/INF.0000000000003309
Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19
Conflict of interest statement
The authors have no funding or conflicts of interest to disclose.
Comment on
-
Sinus Bradycardia in Children Treated With Remdesivir for COVID-19.Pediatr Infect Dis J. 2021 Sep 1;40(9):e356. doi: 10.1097/INF.0000000000003214. Pediatr Infect Dis J. 2021. PMID: 34285169 No abstract available.
References
-
- Eleftheriou I, Liaska M, Krepis P, et al. . Sinus bradycardia in children treated with remdesivir for COVID-19 [published online ahead of print July 19, 2021]. Pediatr Infect Dis J. doi: 10.1097/INF.0000000000003214 - PubMed
-
- Avataneo V, de Nicolò A, Cusato J, et al. . Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. J Antimicrob Chemother. 2020;75:1772–1777. - PMC - PubMed
-
- Goldman DL, Aldrich ML, Hagmann SHF, et al. . Compassionate use of remdesivir in children with severe COVID-19. Pediatrics. 2021;147:e2020047803. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources